MIRD Monograph: Radiobiology and Dosimetry for Radiopharmaceutical Therapy with Alpha-Particle Emitters

MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.

The potential of alpha-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry, and the increased availability of alpha-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with alpha-particle emitters. Although alpha-emitters have ...

MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature.

The internal dosimetry schema of the Medical Internal Radiation Dose (MIRD) Committee of the Society of Nuclear Medicine has provided a broad framework for assessment of the absorbed dose to whole organs, tissue subregions, voxelized tissue structures, and individual cellular compartments for use in both diagnostic and therapeutic nuclear medicine. The schema was originally published in 1968, r...

Alpha - Particle Emitter Therapy : Overview , Current Status , and Dosimetry

alpha-Particle emitters in radioimmunotherapy: new and welcome challenges to medical internal dosimetry.

Over the past decade, there has been progressively stronger interest in the use of a-particle emitters for radioimmunotherapy (1–6). With proper localization of the labeled antibody, the high linear energy transfer of a-particles provides a correspondingly high probability of mitotic cell kill when compared with an equivalent number of cellular traversals by lower linear energy transfer b-parti...

Dosimetry of Nano-Radio-Ytterbium Therapy by MIRD and MCNP methods for humans’ organs

Introduction: Nano radio-pharmaceutical therapy (NRPT) is a new method for solid tumor therapy. The treatment uses a radioactive form of radionuclide encapsulated in the poly amido amine dendrimers. The poly (amidoamine) (PAMAM) dendrimers have attracted attentions for cancer treatment by their characteristics of targeted drug carriers, delivery agents, and imaging agents in hu...